New Journey(SZ:002219) 经济观察报·2025-07-07 09:39Core Viewpoint - The company New Mileage (002219.SZ) is undergoing a leadership change due to the chairman Lin Yanglin being placed under investigation, with the board appointing Xu Minggui as acting chairman during this period [2][4]. Group 1: Company Leadership and Governance - Lin Yanglin has been notified by his family that he is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties [2][4]. - The company has confirmed that the investigation is unrelated to its operations and has not been asked to assist in the investigation [3][4]. - The board has a robust governance and internal control mechanism in place, ensuring that other directors, supervisors, and senior management continue to perform their duties normally [4]. Group 2: Company Operations and Financials - New Mileage's core business focuses on medical services and the pharmaceutical industry, managing over 40 hospitals across nearly 20 provinces in China, with a total bed capacity of 30,000, ranking among the top three in the country [4]. - The company reported a revenue of 3.8 billion yuan and a net profit of 115 million yuan for the year 2024 [6]. - Lin Yanglin has been the chairman since March 2021, receiving a salary of 36,800 yuan in 2024 and holding 26 million shares at the end of the period [6]. Group 3: Market Reaction - Following the announcement of Lin Yanglin's investigation, the company's stock opened lower, experiencing a drop of over 5% at one point, ultimately closing down 3.69%, with a total market capitalization of 7.1 billion yuan [10].